ELMMB logo
Facebook logo Twitter logo
Menu
Drug Alerts and Withdrawals

Drug Alerts and Withdrawals

Within the UK, the Medicines and Healthcare products Regulatory Agency (MHRA), an executive agency of the Department of Health aim to enhance and safeguard the health of the public by ensuring that medicines and medical devices work and are acceptably safe. No product is risk-free. Underpinning their work lie robust and fact-based judgements to ensure that the benefits to patients and the public justify the risks.

  • The Medicines and Healthcare products Regulatory Agency (MHRA) is the government agency which is responsible for ensuring that medicines and medical devices work, and are acceptably safe.
  • No product is risk-free. Underpinning the work of the MHRA lie robust and fact-based judgements to ensure that the benefits to patients and the public justify the risks.
  • The MHRA keep watch over medicines and devices, and take any necessary action to protect the public promptly if there is a problem.
  • The MHRA aim to make as much information as possible publicly available. The MHRA enable greater access to products, and the timely introduction of innovative treatments and technologies that benefit patients and the public.
  • The MHRA encourage everyone - the public and healthcare professionals as well as industry - to tell us about any problems with a medicine or medical device, so that we can investigate and take any necessary action. To find out more about the MHRA click here...

When the MHRA, or occasionally another regulatory body in another country, such as the FDA, release advice, it is sometime necessary to produce additional local guidance.  This aims to be both clear and concise advice to healthcare professionals on the local action required to implement or respond to alerts issued by the MHRA or other bodies.  These memorandums are available below for reference, once they have been circulated to the relevant professionals in primary and secondary care:

MHRA News Stories.

 4th March 2020            MHRA Press Release - Patients asked to return Emerade 150 micrograms adrenaline pens
 24th February 2020     MHRA Guidance - Coronavirus (COVID-19): latest information and advice
12th February 2020      MHRA Press Release  - Integrated Yellow Card reporting now available in 93% of GP practices in the UK
19th November 2019   MHRA Press Release - Ranitidine Oral Solution & Tablets recall
26th September 2019  MHRA Press Release - Contact lenses recall: 1-day Acuvue mMoist for Astigmatism
23rd September 2019  MHRA Press Release - Two benzoyl peroxide products to treat mild acne affecting the face to go on general sale
19th September 2019  MHRA Update - Update on licensing status of Avastin when intended for intravitreal administration
30th August 2019         MHRA Update - HRT users to discuss its risks and benefits at their next routine appointment as new study
                                                                   highlights persistent risk of breast cancer
1st August 2019           MHRA Update -  First Allergy Test for hair dye to go on general sale
26th July 2019              MHRA News Story - MHRA takes action to ensure product safety for patients supplied with total parenteral
                                                                         nutrition bags from the Calea UK/Fresenius Kabi manufacturing facility in Runcorn


MHRA Company-led Drug alerts

click here to access the most recent alerts

Items In This Category

 TitleCreatedDownload
application/pdfFolic Acid 5mg tabs_accord_UK_ Cl3 meds recall_EL__19_A_35_Final.pdf (108KB)19/11/2019Download
 Accord-UK Ltd has informed us of an issue related to decommissioning of the above batch. Upon decommissioning at the pharmacy, there have been reports stating that when scanning the serialised 2D... 
application/pdfSayana Press Class 2 Medicines recall Sayana Press Oct 19.pdf (138KB)23/10/2019Download
 Pfizer Ltd has informed us of an issue related to the sealing process for some units of Sayana Press for subcutaneous (SC) injection potentially impacting the above listed batches. Sayana Press for... 
application/pdfRifadin_Rifampicin 150mg capsules CLASS 4 MEDICINES DEFECT INFORMATION October 2019.pdf (129KB)23/10/2019Download
 Sanofi has informed us that a change to the Patient Information Leaflet (PIL) for this product has not been implemented by the required timeline.  
application/pdfXonvea 10mg Class 4 Medicines Recall__October 2019.pdf (127KB)23/10/2019Download
 Alliance Pharmaceuticals Ltd has informed us that the Patient Information Leaflet (PIL) is missing the possible side effects from post-marketing experience and the associated class effects that are... 
application/pdfClass 2 medicines recall: Ranitidine Effervescent Tablets Drug alert_Oct 19.pdf (194KB)23/10/2019Download
 Teva UK Limited trading as ratiopharm GmbH is recalling all unexpired stock of Ranitidine Effervescent Tablets from pharmacies. 
application/pdfBisacodyl 10mg supppositories Class 2 meds recall 230919.pdf (107KB)27/09/2019Download
 Martindale Pharmaceuticals Limited is recalling the above batch due to an issue with homogeneity. This may result in individual suppositories containing too little or too much active substance.... 
application/pdfAripiprazole 1mg per ml oral soln_class 2 meds recall 0719.pdf (147KB)31/07/2019Download
 Accord-UK Ltd is recalling the above batches due to the potential for small particles of Aripiprazole active material to be present which may affect the efficacy of the product. No relevant product... 
application/pdfBisacodyl 5mg GR tabs_Chanelle Medical Class 2 meds recall 0719_Final.pdf (191KB)31/07/2019Download
 Chanelle Medical is recalling the above batch because a small number of packs have been found to contain tablets which are stuck together, with mould observed on some tablets. The mould has been... 
application/pdfPhenobarbital sod 30mg permL injection Cl 4 meds defect info EL__19__A_16_Final_.pdf (181KB)08/07/2019Download
 phenobarb, elixir 
application/pdfMHRA FMD Alert B&S Healthcare 0619 EL__19_A15_final_.pdf (249KB)28/06/2019Download
 Falsified medicines have entered the UK supply chain at pharmacy and patient level. The products have been parallel imported into the UK by B & S Healthcare from Italy and have been re-labelled or... 
application/pdfParacetamol 500mg tabs 1x1000 M&A Pharma MHRA Class 2 medicines recall 130619.pdf (113KB)13/06/2019Download
 M & A Pharmachem is recalling the above batches because a small number of pots from each batch have been found to contain discoloured tablets due to fungal contamination. The fungi have been... 
application/pdfPotassium Chloride_Baxter_iv infusions Class 4 Drug Alert 030619.pdf (624KB)03/06/2019Download
 Baxter Healthcare have identified a quality defect with products included in this drug alert. 
Page: [1] [2] [3] [4] [5]